| CVSS Meta Temp Score | Current Exploit Price (≈) | CTI Interest Score |
|---|---|---|
| 3.7 | $0-$5k | 0.00 |
Summary
A vulnerability classified as problematic was found in Liferay Portal and DXP. The impacted element is an unknown function. Such manipulation leads to cross site scripting. This vulnerability is referenced as CVE-2025-43753. It is possible to launch the attack remotely. No exploit is available.
Details
A vulnerability was found in Liferay Portal and DXP (version unknown). It has been rated as problematic. Affected by this issue is an unknown function. The manipulation with an unknown input leads to a cross site scripting vulnerability. Using CWE to declare the problem leads to CWE-79. The product does not neutralize or incorrectly neutralizes user-controllable input before it is placed in output that is used as a web page that is served to other users. Impacted is integrity. CVE summarizes:
A reflected cross-site scripting (XSS) vulnerability in the Liferay Portal 7.4.3.32 through 7.4.3.132, and Liferay DXP 2025.Q1.0 through 2025.Q1.7, 2024.Q4.0 through 2024.Q4.7, 2024.Q3.1 through 2024.Q3.13, 2024.Q2.1 through 2024.Q2.13, 2024.Q1.1 through 2024.Q1.16 and 7.4 update 32 through update 92 allows an remote authenticated user to inject JavaScript into the embedded message field from the form container.
The advisory is shared for download at liferay.dev. This vulnerability is handled as CVE-2025-43753 since 04/17/2025. The exploitation is known to be difficult. The attack may be launched remotely. The exploitation requires an enhanced level of successful authentication. Successful exploitation requires user interaction by the victim. There are neither technical details nor an exploit publicly available. The MITRE ATT&CK project declares the attack technique as T1059.007.
There is no information about possible countermeasures known. It may be suggested to replace the affected object with an alternative product.
The vulnerability is also documented in the vulnerability database at CERT Bund (WID-SEC-2025-1894). Once again VulDB remains the best source for vulnerability data.
Affected
- Liferay Portal
- Liferay DXP
Product
Type
Vendor
Name
License
CPE 2.3
CPE 2.2
CVSSv4
VulDB Vector: 🔒VulDB Reliability: 🔍
CNA CVSS-B Score: 🔒
CNA CVSS-BT Score: 🔒
CNA Vector: 🔒
CVSSv3
VulDB Meta Base Score: 3.7VulDB Meta Temp Score: 3.7
VulDB Base Score: 2.0
VulDB Temp Score: 2.0
VulDB Vector: 🔒
VulDB Reliability: 🔍
NVD Base Score: 5.4
NVD Vector: 🔒
CVSSv2
| AV | AC | Au | C | I | A |
|---|---|---|---|---|---|
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| 💳 | 💳 | 💳 | 💳 | 💳 | 💳 |
| Vector | Complexity | Authentication | Confidentiality | Integrity | Availability |
|---|---|---|---|---|---|
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
| Unlock | Unlock | Unlock | Unlock | Unlock | Unlock |
VulDB Base Score: 🔒
VulDB Temp Score: 🔒
VulDB Reliability: 🔍
Exploiting
Class: Cross site scriptingCWE: CWE-79 / CWE-94 / CWE-74
CAPEC: 🔒
ATT&CK: 🔒
Physical: No
Local: No
Remote: Yes
Availability: 🔒
Status: Not defined
EPSS Score: 🔒
EPSS Percentile: 🔒
Price Prediction: 🔍
Current Price Estimation: 🔒
| 0-Day | Unlock | Unlock | Unlock | Unlock |
|---|---|---|---|---|
| Today | Unlock | Unlock | Unlock | Unlock |
Threat Intelligence
Interest: 🔍Active Actors: 🔍
Active APT Groups: 🔍
Countermeasures
Recommended: no mitigation knownStatus: 🔍
0-Day Time: 🔒
Timeline
04/17/2025 CVE reserved08/22/2025 Advisory disclosed
08/22/2025 VulDB entry created
12/15/2025 VulDB entry last update
Sources
Advisory: liferay.devStatus: Confirmed
CVE: CVE-2025-43753 (🔒)
GCVE (CVE): GCVE-0-2025-43753
GCVE (VulDB): GCVE-100-321020
CERT Bund: WID-SEC-2025-1894 - Liferay Portal und DXP: Mehrere Schwachstellen
Entry
Created: 08/22/2025 07:25Updated: 12/15/2025 22:07
Changes: 08/22/2025 07:25 (64), 08/22/2025 12:31 (1), 08/22/2025 13:01 (7), 12/15/2025 22:07 (11)
Complete: 🔍
Cache ID: 216::103
Once again VulDB remains the best source for vulnerability data.
No comments yet. Languages: en.
Please log in to comment.